A major advancement in the field of medicine has been the introduction and usage of direct
oral anticoagulants (DOACs) such as dabigatran (Pradaxa), apixaban (Eliquis), and …

Background The efficacy and safety of non-vitamin K antagonist oral anticoagulants
(NOACs) compared with warfarin in patients with atrial fibrillation (AF) and peripheral artery …

Background Non-valvular atrial fibrillation (NVAF) is the most common cause of cardiogenic
cerebral embolism (CCE). However, the underlying mechanism between cerebral embolism …

Objectives To investigate the relationship between the initiation time of anticoagulation after
endovascular treatment (EVT) and the outcomes in atrial fibrillation (AF)-related acute …

Aims Patients with cancer are at higher risk of atrial fibrillation, thromboembolic
complications and bleeding events compared with the general population. The aim of the …

To evaluate analytic and clinical performance of plasma thrombin–antithrombin complex
(TAT) and d-dimer assay in assessing the severity and outcome of acute ischemic stroke …

In recent times, novel oral anticoagulants (NOACs)/direct oral anticoagulants (DOACs) have
emerged as an alternative to the traditionally used Vitamin K oral antagonists (VKA) like …

Background The purpose of this meta-analysis was to compare efficacy and safety of direct
oral anticoagulants (DOACs) to warfarin for secondary stroke prevention among adult …

Background Bleeding risk factors in elderly patients with atrial fibrillation undergoing
percutaneous coronary intervention (PCI) are unclear and data on the use of antithrombotic …

Background: Patients with non-valvular atrial fibrillation with diabetes face increased stroke
and cardiovascular risks. This study compares factor Xa inhibitors and warfarin using data …